• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus

    6/12/24 8:58:00 AM ET
    $SLP
    EDP Services
    Technology
    Get the next $SLP alert in real time by email

    QHP Capital, L.P. ("QHP"), an investor in technology and services companies in the life sciences and healthcare sectors, today announced its sale of Pro-ficiency, LLC ("Pro-ficiency" or the "Company"), a leader in providing tech-enabled training and compliance solutions for clinical trial investigators and site staff, to Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy.

    Michael Raymer, Chief Executive Officer of Pro-ficiency, said, "We are excited to join the Simulations Plus team, which has a well-established and recognized leadership position in modeling and simulations within the pharmaceutical and biotech community. Both teams approached this transaction with a growth mentality. We look forward to leveraging Simulations Plus' specialized offerings and business development infrastructure to expand our combined market reach. Finally, our operations are complementary, our cultures are aligned, and together we believe we can elevate the performance of our mutual clients as well as attract new ones with our end-to-end solutions."

    QHP Capital made its original investment in Pro-ficiency in 2021. The Company then completed several additional acquisitions in the investment period with Fugitive Labs, LLC in 2022 and Compass Group Partners in 2023.

    "We are very pleased with the growth and innovation we have seen these past few years at Pro-ficiency. We are excited to see them continue to improve clinical development as part of the SLP offering," said Michael Sorensen, Partner at QHP Capital.

    About Pro-ficiency:

    Pro-ficiency is a leading provider of tech-enabled training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including a turn-key offering of customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. For more information, please visit www.pro-ficiency.com.

    About Simulations Plus, Inc:

    Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. For more information, please visit www.simulations-plus.com.

    About QHP Capital:

    QHP Capital is an investor in technology and services companies in the life sciences and healthcare sectors. QHP Capital spun out of NovaQuest Capital Management, which was formed in 2000 with the vision of building an investment platform to provide strategic capital and industry expertise in partnership with strong management teams. The investment team consists of seasoned investment and operational professionals with significant investment experience and deep life science and healthcare expertise. QHP benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing QHP's portfolio companies. QHP continues as the investment manager for NovaQuest Private Equity funds. For more information, please visit www.qhpcapital.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240611617725/en/

    Get the next $SLP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLP

    DatePrice TargetRatingAnalyst
    11/15/2024$39.00Overweight
    Stephens
    7/29/2024$47.00Overweight
    KeyBanc Capital Markets
    7/16/2024Mkt Perform
    JMP Securities
    6/28/2024Outperform
    William Blair
    5/9/2023$55.00Buy
    BTIG Research
    10/26/2021$65.00 → $53.00Hold → Buy
    Craig Hallum
    7/13/2021$95.00 → $54.00Outperform
    Raymond James
    More analyst ratings

    $SLP
    SEC Filings

    See more
    • Simulations Plus Inc. filed SEC Form 8-K: Leadership Update, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - Simulations Plus, Inc. (0001023459) (Filer)

      6/2/25 7:55:20 AM ET
      $SLP
      EDP Services
      Technology
    • Simulations Plus Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Simulations Plus, Inc. (0001023459) (Filer)

      4/18/25 8:34:07 AM ET
      $SLP
      EDP Services
      Technology
    • SEC Form 10-Q filed by Simulations Plus Inc.

      10-Q - Simulations Plus, Inc. (0001023459) (Filer)

      4/4/25 7:55:42 AM ET
      $SLP
      EDP Services
      Technology

    $SLP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Simulations Plus Inc.

      SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)

      8/8/24 2:18:03 PM ET
      $SLP
      EDP Services
      Technology
    • SEC Form SC 13G/A filed by Simulations Plus Inc. (Amendment)

      SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)

      2/13/24 5:13:58 PM ET
      $SLP
      EDP Services
      Technology
    • SEC Form SC 13G/A filed by Simulations Plus Inc. (Amendment)

      SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)

      2/12/24 4:59:04 PM ET
      $SLP
      EDP Services
      Technology

    $SLP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Woltosz Walter S sold $543,074 worth of shares (20,000 units at $27.15), decreasing direct ownership by 0.60% to 3,324,157 units (SEC Form 4)

      4 - Simulations Plus, Inc. (0001023459) (Issuer)

      6/3/25 4:57:16 PM ET
      $SLP
      EDP Services
      Technology
    • Director Woltosz Walter S was granted 786 shares and sold $670,150 worth of shares (20,000 units at $33.51), decreasing direct ownership by 0.57% to 3,344,157 units (SEC Form 4)

      4 - Simulations Plus, Inc. (0001023459) (Issuer)

      5/1/25 5:53:05 PM ET
      $SLP
      EDP Services
      Technology
    • Director Evans Sharlene was granted 786 shares, increasing direct ownership by 9% to 9,435 units (SEC Form 4)

      4 - Simulations Plus, Inc. (0001023459) (Issuer)

      5/1/25 4:27:34 PM ET
      $SLP
      EDP Services
      Technology

    $SLP
    Leadership Updates

    Live Leadership Updates

    See more
    • QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus

      QHP Capital, L.P. ("QHP"), an investor in technology and services companies in the life sciences and healthcare sectors, today announced its sale of Pro-ficiency, LLC ("Pro-ficiency" or the "Company"), a leader in providing tech-enabled training and compliance solutions for clinical trial investigators and site staff, to Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy. Michael Raymer, Chief Executive Officer of Pro-ficiency, said, "We are excited to join the Simulations Plus team, which has a well-established and recognized leadership position in modeling and simulations wi

      6/12/24 8:58:00 AM ET
      $SLP
      EDP Services
      Technology
    • Simulations Plus Names Industry Veteran Will Frederick as Chief Financial Officer

      LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today the appointment of Will Frederick as chief financial officer (CFO), succeeding John Kneisel, who retires after seven years with the company. Will Frederick brings more than 25 years of financial leadership experience to the company. He has a proven track record of developing and implementing strategies to drive revenue growth, increase profitability, managing merger & acquisition activities and achieving corporate objectives. He has global experience with both publicly traded and privately held companies including Pharsight, Entelos, Avaya, The Walt Disney Company and Ford Motor Company, among

      12/1/20 4:05:00 PM ET
      $DIS
      $SLP
      $F
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
      EDP Services
      Technology

    $SLP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Simulations Plus Releases ADMET Predictor® 13

      Expanded functionality and advanced AI/ML capabilities deliver faster, more accurate predictions and streamline enterprise deployment Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-thr

      6/5/25 7:50:00 AM ET
      $SLP
      EDP Services
      Technology
    • Simulations Plus Releases DILIsym® 11

      Newest version of the quantitative systems toxicology (QST) software supports drug-induced liver injury (DILI) prediction for pediatric patient populations Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym® 11, the latest version of its flagship quantitative systems toxicology (QST) platform. "Advancing toxicology research and improving the prediction of drug-induced liver injury (DILI) are essential to developing safer treatments," said Shawn O'Connor, Chief Executive Officer o

      5/15/25 7:50:00 AM ET
      $SLP
      EDP Services
      Technology
    • Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies

      Modeling and simulation will be a key component for shift to non-animal methodologies Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy combined with built-in coaching and training Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration's (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the i

      4/21/25 7:50:00 AM ET
      $SLP
      EDP Services
      Technology

    $SLP
    Financials

    Live finance-specific insights

    See more
    • Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results

      Total revenue grew 23% year-over-year driven by strong growth in both software and services Maintains full-year revenue guidance of $90 to $93 million and adjusted diluted EPS of $1.07 to $1.20 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its second quarter fiscal 2025, ended February 28, 2025. Second Quarter 2025 Financial Highlights (as compared to second quarter 2024) Total revenue increased 23% to $22.4 million Software revenue increased 16% to $13.5 million, repres

      4/3/25 4:05:00 PM ET
      $SLP
      EDP Services
      Technology
    • Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date

      Conference call to be on Thursday, April 3, 2025, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will report second quarter fiscal 2025 financial results after the market close on Thursday, April 3, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accesse

      3/20/25 7:00:00 AM ET
      $SLP
      EDP Services
      Technology
    • Simulations Plus Reports First Quarter Fiscal 2025 Financial Results

      Total revenue up 31% year-over-year primarily driven by strong software growth Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial Highlights (compared to first quarter 2024) Total revenue increased 31% to $18.9 million Software revenue increased 41% to $10.7 million, representing 57% of total revenue Services revenue increased 19% to $8.2 million, representing 43% of total revenue Gro

      1/7/25 4:06:00 PM ET
      $SLP
      EDP Services
      Technology

    $SLP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on Simulations Plus with a new price target

      Stephens initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $39.00

      11/15/24 8:20:56 AM ET
      $SLP
      EDP Services
      Technology
    • KeyBanc Capital Markets initiated coverage on Simulations Plus with a new price target

      KeyBanc Capital Markets initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $47.00

      7/29/24 7:43:47 AM ET
      $SLP
      EDP Services
      Technology
    • JMP Securities initiated coverage on Simulations Plus

      JMP Securities initiated coverage of Simulations Plus with a rating of Mkt Perform

      7/16/24 7:49:15 AM ET
      $SLP
      EDP Services
      Technology